Seeking Alpha

Aeterna Zentaris (AEZS +2%) gains today after saying earlier that its oral AKT inhibitor...

Aeterna Zentaris (AEZS +2%) gains today after saying earlier that its oral AKT inhibitor perifosine, when combined with temsirolimus, was well tolerated while treating recurrent or progressive malignant glioma during Phase 1 clinical trials.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|